Comparison of Telmisartan a blood pressure lowering agent with other blood pressure lowering agents on its effects on insulin sensitivity, inflammation and vascular function in patients of type 2 diabetes with high blood pressure : an open label interventional study

INTERVENTION: Intervention1: Telmisartan 40mg: Telmisartan is given 40mg orally once daily for 3 months as per the standard treatment guidelines in patients of T2DM newly diagnosed with hypertension Control Intervention1: Any other anti‐hypertensive in the standard dose: Any other anti ‐ hypertensive like amlodipine 5 or 10mg once daily orally or ramipril 5mg or 10mg once daily orally or cilnidipine orally 10mg Once Daily or twice daily as per the physician choice and according to dose requirement as per the standard treatment guidelines is administered for 3 months in patients of T2DM with newly diagnosed hypertension. CONDITION: Health Condition 1: I10‐ Essential (primary) hypertension Health Condition 2: E119‐ Type 2 diabetes mellitus without complications PRIMARY OUTCOME: To compare the effect of telmisartan with other anti hypertensives on insulin resistance in terms of HOMA IR valuesTimepoint: Baseline and after three months SECONDARY OUTCOME: compare the effect of telmisartan with other anti‐hypertensives on the levels of inflammatory marker CRPTimepoint: Baseline and after 3 months To compare the effect of telmisartan with other anti‐hypertensives on the levels of inflammatory markers IL 6Timepoint: Baseline and after 3 months To compare the effect of telmisartan with other anti‐hypertensives on the levels of inflammatory markers TNF alphaTimepoint: Baseline and after 3 months To compare the effect of telmisartan with other anti‐hypertensives on the levels of vascular endothelin 1Timepoint: Baseline and after 3 months INCLUSION CRITERIA: 18‐75 years of age SBP >140 mmHg DBP >90mmHg Diagnosed case of T2DM HbA1c between 7% and 10% Patients on metformin and /or DPP4 inhibitors